GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » Altman Z-Score

Cantel Medical (Cantel Medical) Altman Z-Score : 3.10 (As of Apr. 26, 2024)


View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical Altman Z-Score?

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Good Sign:

Altman Z-score of 3.09 is strong.

Cantel Medical has a Altman Z-Score of 3.10, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Cantel Medical's Altman Z-Score or its related term are showing as below:

CMD' s Altman Z-Score Range Over the Past 10 Years
Min: 1.98   Med: 4.73   Max: 18.01
Current: 3.09

During the past 13 years, Cantel Medical's highest Altman Z-Score was 18.01. The lowest was 1.98. And the median was 4.73.


Cantel Medical Altman Z-Score Historical Data

The historical data trend for Cantel Medical's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantel Medical Altman Z-Score Chart

Cantel Medical Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.14 9.46 8.65 7.63 2.12

Cantel Medical Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.98 2.12 2.29 2.95 3.23

Competitive Comparison of Cantel Medical's Altman Z-Score

For the Medical Instruments & Supplies subindustry, Cantel Medical's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantel Medical's Altman Z-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cantel Medical's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Cantel Medical's Altman Z-Score falls into.



Cantel Medical Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Cantel Medical's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*0.1886+1.4*0.2983+3.3*0.0647+0.6*2.8011+1.0*0.5604
=3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Apr. 2021:
Total Assets was $2,031 Mil.
Total Current Assets was $626 Mil.
Total Current Liabilities was $243 Mil.
Retained Earnings was $606 Mil.
Pre-Tax Income was 30.679 + 16.138 + 34.059 + -11.43 = $69 Mil.
Interest Expense was -14.845 + -15.491 + -16.293 + -15.273 = $-62 Mil.
Revenue was 313.953 + 294.038 + 297.029 + 233.371 = $1,138 Mil.
Market Cap (Today) was $3,401 Mil.
Total Liabilities was $1,214 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(625.997 - 242.954)/2031.278
=0.1886

X2=Retained Earnings/Total Assets
=605.984/2031.278
=0.2983

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(69.446 - -61.902)/2031.278
=0.0647

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=3400.793/1214.088
=2.8011

X5=Revenue/Total Assets
=1138.391/2031.278
=0.5604

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Cantel Medical has a Altman Z-Score of 3.10 indicating it is in Safe Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.


Cantel Medical  (NYSE:CMD) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Cantel Medical Altman Z-Score Related Terms

Thank you for viewing the detailed overview of Cantel Medical's Altman Z-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantel Medical (Cantel Medical) Business Description

Traded in Other Exchanges
N/A
Address
150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424
Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.
Executives
Ann E Berman director 255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann officer: SVP, General Counsel 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades director, officer: Chief Executive Officer 281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker director, 10 percent owner, officer: Chairman ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman officer: SVP - CFO C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner officer: SVP and CHRO 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone officer: SVP and Princ. Accounting Ofr 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford officer: President and COO 40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin officer: Executive Vice President 150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese director 849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost director JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin director C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers director TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin director 399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316

Cantel Medical (Cantel Medical) Headlines

From GuruFocus

Cantel Hires Michael Drexel to SVP and Chief Technology Officer

By PRNewswire PRNewswire 10-01-2020